期刊文献+

丙型肝炎病毒5个基因的正选择位点研究 被引量:2

Assay on the positively selected sites of five genes of hepatitis C virus
下载PDF
导出
摘要 按照时间和亚型筛选丙型肝炎病毒5个主要基因(E1、E2、NS3、NS5A和NS5B)的正选择位点,并分析其变化规律。研究结果表明这些基因在总体上均受到纯化选择压力(平均ω<1),且大小依次是E2<E1<NS5A<NS5B<NS3;进一步的分子进化分析鉴定出多个正选择位点,且随着时间的变化,每个基因的正选择位点并非恒定,数目不断增加,位置不断更替;同一基因三个亚型间的正选择位点也不尽相同,1a亚型的正选择位点数目最多,1b亚型次之,3a亚型最少,这些结果使得对HCV的进化规律有了进一步的理解。 The positively selected sites for the five major genes(E1,E2,NS3,NS5A and NS5B)of HCV were analyzed from the perspective of time and subtype,and the pattern of variation of these positively selected sites was studied.The Result of this assay showed that the five genes were generally subject to purifying selection(mean ω1),and the order of the purifying selection pressure on them was E2E1NS5ANS5BNS3.Through molecular evolution analysis,lots of positively selected sites were detected,and these positively selected sites of HCV were not always same in different periods.The number of them was increasing and the position was constantly changing over time.Besides,in different subtypes,the number and the position of positively selected sites were also not same completely,the number was largest for subtype 1a,followed by subtype 1b,and subtype 3a was the minimum.
出处 《生物学杂志》 CAS CSCD 2012年第6期23-28,共6页 Journal of Biology
关键词 丙型肝炎病毒 时间 亚型 正选择位点 hepatitis C Virus time subtype positively selected site
  • 相关文献

参考文献6

二级参考文献120

  • 1张文彤,姜庆五,蒋露芳,居丽雯.基于基因序列聚类的甲型流行性感冒病毒H3抗原变异规律研究[J].中华流行病学杂志,2004,25(12):1046-1049. 被引量:8
  • 2于振宝,匡廷云,卢荣禾,唐崇钦,汤佩松.光下D1/D2/Cytb559复合物中氨基酸残基的破坏和多肽的降解[J].Acta Botanica Sinica,1995,37(4):267-273. 被引量:1
  • 3张文彤,姜庆五.全球历年人甲型流感病毒H3A1抗原的分子进化研究[J].中华流行病学杂志,2005,26(11):843-847. 被引量:11
  • 4Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
  • 5Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004; 63:71-180.
  • 6Shiffman ML. Impact of peginterferon maintenance ther- apy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. Oncology 2010; 78 Suppl 1:11-16.
  • 7Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastro- enterology 2009; 136:138-148.
  • 8Kato N. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb Comp Genomics 2000; 5" 129-151.
  • 9Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genoWves 2 or 3. J Hepato12004; 40:993-999.
  • 10Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchausp~ G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM,Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified sys- tem of nomenclature of hepatitis C virus genotypes. Hepatol- ogy 2005; 42:962-973.

共引文献22

同被引文献14

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部